Liquidia Corp
NASDAQ:LQDA

Watchlist Manager
Liquidia Corp Logo
Liquidia Corp
NASDAQ:LQDA
Watchlist
Price: 11.42 USD 1.51% Market Closed
Market Cap: 959.3m USD
Have any thoughts about
Liquidia Corp?
Write Note

Relative Value

The Relative Value of one LQDA stock under the Base Case scenario is 4.2 USD. Compared to the current market price of 11.42 USD, Liquidia Corp is Overvalued by 63%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LQDA Relative Value
Base Case
4.2 USD
Overvaluation 63%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
14
vs Industry
5
Median 3Y
25.9
Median 5Y
25.4
Industry
2.5
Forward
60.3
vs History
vs Industry
Median 3Y
-8.2
Median 5Y
-7.1
Industry
21.9
Forward
-6.8
vs History
vs Industry
Median 3Y
-12.1
Median 5Y
-9.2
Industry
16.5
vs History
vs Industry
Median 3Y
-17.6
Median 5Y
-11.6
Industry
23.6
vs History
30
vs Industry
7
Median 3Y
6.8
Median 5Y
4.8
Industry
2.1
vs History
17
vs Industry
5
Median 3Y
22.6
Median 5Y
20.8
Industry
2.6
Forward
53.8
vs History
11
vs Industry
3
Median 3Y
27.2
Median 5Y
25
Industry
5.2
vs History
vs Industry
Median 3Y
-8.9
Median 5Y
-6.4
Industry
13.3
Forward
-7
vs History
vs Industry
Median 3Y
-8.4
Median 5Y
-5.9
Industry
16.6
Forward
-7.3
vs History
vs Industry
Median 3Y
-11.1
Median 5Y
-7.5
Industry
15.6
vs History
vs Industry
Median 3Y
-9.4
Median 5Y
-7.5
Industry
19.1
vs History
19
vs Industry
6
Median 3Y
11.4
Median 5Y
10.1
Industry
1.9

Multiples Across Competitors

LQDA Competitors Multiples
Liquidia Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Liquidia Corp
NASDAQ:LQDA
965.5m USD 61.9 -8.1 -7.9 -7.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
749.7B USD 18.3 89.6 48.1 53.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.2 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
372B USD 4.2 25.3 12.2 15.9
US
Merck & Co Inc
NYSE:MRK
257.3B USD 4.1 21.2 10.7 12.8
CH
Roche Holding AG
SIX:ROG
201.7B CHF 3.4 17.5 9.9 11.7
UK
AstraZeneca PLC
LSE:AZN
163B GBP 4.2 31.8 169.5 254
CH
Novartis AG
SIX:NOVN
179.6B CHF 4.1 11.5 9.9 13.9
US
Pfizer Inc
NYSE:PFE
146B USD 2.4 34.3 10.3 15.6
P/E Multiple
Earnings Growth
US
Liquidia Corp
NASDAQ:LQDA
Average P/E: 33.3
Negative Multiple: -8.1
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
89.6
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.3
-22%
US
Merck & Co Inc
NYSE:MRK
21.2
7 321%
CH
Roche Holding AG
SIX:ROG
17.5
32%
UK
AstraZeneca PLC
LSE:AZN
31.8
177%
CH
Novartis AG
SIX:NOVN
11.5
21%
US
Pfizer Inc
NYSE:PFE
34.3
733%
EV/EBITDA Multiple
EBITDA Growth
US
Liquidia Corp
NASDAQ:LQDA
Average EV/EBITDA: 460.2
Negative Multiple: -7.9
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A
US
Eli Lilly and Co
NYSE:LLY
48.1
195%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
DK
Novo Nordisk A/S
CSE:NOVO B
24.3
84%
US
Johnson & Johnson
NYSE:JNJ
12.2
14%
US
Merck & Co Inc
NYSE:MRK
10.7
331%
CH
Roche Holding AG
SIX:ROG
9.9
23%
UK
AstraZeneca PLC
LSE:AZN
169.5
64%
CH
Novartis AG
SIX:NOVN
9.9
8%
US
Pfizer Inc
NYSE:PFE
10.3
31%
EV/EBIT Multiple
EBIT Growth
US
Liquidia Corp
NASDAQ:LQDA
Average EV/EBIT: 2 012
Negative Multiple: -7.7
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A
US
Eli Lilly and Co
NYSE:LLY
53.7
212%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
DK
Novo Nordisk A/S
CSE:NOVO B
27.8
85%
US
Johnson & Johnson
NYSE:JNJ
15.9
29%
US
Merck & Co Inc
NYSE:MRK
12.8
695%
CH
Roche Holding AG
SIX:ROG
11.7
27%
UK
AstraZeneca PLC
LSE:AZN
254
131%
CH
Novartis AG
SIX:NOVN
13.9
54%
US
Pfizer Inc
NYSE:PFE
15.6
63%

See Also

Discover More
Back to Top